Breast Cancer Subtype Characterization Through Patient's Derived Organoids.
Conditions: Breast Cancer; Organoids Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Conditions: HER2-positive Breast Cancer Interventions: Drug: BL-M07D1; Drug: T-DM1 Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
Conditions: Electroacupuncture; Olanzapine-contained Four-drug Antiemetic; Nausea and Vomiting Interventions: Device: Electroacupuncture; Drug: Antiemetic Therapy; Device: Sham electroacupuncture; Drug: Antiemetic Therapy Sponsors: Feixue Song Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Lung Carcinoma; Metastatic Malignant Neoplasm in the Brain; Stage IV Lung Cancer AJCC v8 Interventions: Behavioral: Behavioral Dietary Intervention; Other: Text Message-Based Navigation Intervention; Other: Internet-Based Intervention; Behavioral: Dietary Counseling and Surveillance; Radiation: Stereotactic Radiosurgery; Procedure: Biospecimen Collection; Procedure: Magnetic Resonance Imaging; Other: Neurocognitive Assessment; Other: Questionnaire Administration; Other: Interview; Other: Internet-Based Intervention; Radiation: Ster...
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
Conditions: HER2-positive Breast Cancer Interventions: Drug: DP303c; Drug: trastuzumab emtansine Sponsors: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Hemay022+AI; Drug: Lapatinib+Capecitabine Sponsors: Tianjin Hemay Pharmaceutical Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
Conditions: Breast Cancer Interventions: Drug: First-line Ribociclib + endocrine therapy; Drug: First-line endocrine therapy; Drug: First-line chemtherapy Sponsors: Novartis Pharmaceuticals Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Percent Weight Change in the Medical Supplement Group of Early Breast Cancer
Conditions: Early Stage Breast Cancer Interventions: Dietary Supplement: Ensure Sponsors: Rajavithi Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Contrast-Enhanced Spectral Mammography (CESM)
Conditions: Breast Cancer Interventions: Device: Contrast Enhanced Mammography Sponsors: European Institute of Oncology Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
A Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Conditions: Breast Neoplasms Interventions: Drug: MK-2870; Biological: Pembrolizumab; Drug: Paclitaxel; Drug: Nab-paclitaxel; Drug: Capecitabine; Drug: Liposomal doxorubicin Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
AMH Predicts Postchemotherapy Menopause in Premenopausal Breast Cancer Patients
Conditions: Breast Cancer Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Radiotherapy for Breast Cancer
Conditions: Neoadjuvant Radiotherapy; Breast Cancer Interventions: Radiation: Neoadjuvant radiotherapy; Radiation: adjuvant radiotherapy Sponsors: Changhai Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Decision Impact Study of PreciseDx Breast
Conditions: Breast Cancer Interventions: Other: Standard of Care Sponsors: Precise Dx, Inc.; The Cleveland Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant Therapy
Conditions: Prehabilitation; Breast Cancer; Postmenopause; Resistance Training Interventions: Other: Prehabilitation with resistance-exercise training Sponsors: Universidad de La Frontera Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
Conditions: Metastatic Breast Cancer Interventions: Drug: Eribulin; Drug: Sintilimab Sponsors: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
